Skip to main content
SpringerLink
Log in

The Next Generation of Gout Therapeutics: Ready for Prime Time?

  • INVITED COMMENTARY
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237–241.

    Article  PubMed  CAS  Google Scholar 

  2. Wu XW, Muzny DM, Lee CC, Caskey CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992, 34:78–84.

    Article  PubMed  CAS  Google Scholar 

  3. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516–521.

    Article  PubMed  CAS  Google Scholar 

  4. Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450–2461.

    Article  PubMed  CAS  Google Scholar 

  5. Schumacher HR Jr, Becker MA, Wortmann RL, et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540–1548.

    Article  PubMed  CAS  Google Scholar 

  6. Becker MA, Schumacher HR, Espinoza LR, et al.: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12:R63.

    Article  PubMed  Google Scholar 

  7. Sarawate CA, Brewer KK, Yang W, et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925–934.

    Article  PubMed  Google Scholar 

  8. Sundy JS, B.H.S., Becker MA, et al.: Efficacy and safety of intravenous pegloticase (PGL) in treatment failure gout (TFG): results from GOUT1 and GOUT2. Ann Rheum Dis 2009, 68:318.

  9. Sundy JS, Becker MA, Baraf HS, et al.: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008, 58:2882–2891.

    Article  PubMed  Google Scholar 

  10. Schumacher HR, Terkeltaub R, Knapp HR, et al.: Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy. Arthritis Rheum 2009, 60(Suppl):S410.

    Google Scholar 

  11. Borstad GC, Bryant LR, Abel MP, et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429–2432.

    PubMed  CAS  Google Scholar 

  12. So A, De Meulemeester M, Pikhlak A, et al.: Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064–3076.

    Article  PubMed  CAS  Google Scholar 

  13. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ: Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993, 20:111–113.

    PubMed  CAS  Google Scholar 

  14. Siegel LB, Alloway JA, Nashel DJ: Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994, 21:1325–1327.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

Dr. Abeles has served as a consultant for Novartis and on the speakers’ bureau for Takeda Pharmaceuticals North America. Dr. Pillinger reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. University of Connecticut School of Medicine, Farmington, CT, USA

    Aryeh M. Abeles

  2. Department of Rheumatology, New York University School of Medicine/New York University Hospital for Joint Diseases, 301 East 17th Street, Room 1410, New York, NY, 10003, USA

    Michael H. Pillinger

Authors
  1. Aryeh M. Abeles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael H. Pillinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael H. Pillinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abeles, A.M., Pillinger, M.H. The Next Generation of Gout Therapeutics: Ready for Prime Time?. Curr Rheumatol Rep 13, 100–102 (2011). https://doi.org/10.1007/s11926-010-0153-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0153-7

Keywords

Search

Navigation